Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP) reported a remarkable 72% revenue growth in Q1 2022, reaching $69.4 million, compared to $40.4 million in Q1 2021. The U.S. revenue surged by 76% to $66.4 million. The company's gross margin improved to 85.6%, up from 85.2%. Inspire activated 74 new medical centers, totaling 733 centers, and expanded to 17 new sales territories. The company raised its full-year revenue guidance to $336 million to $344 million, from $318 million to $326 million, anticipating continued positive trends.

Inspire Medical Systems (NYSE: INSP) has announced a $10 million investment in EnsoData to improve sleep lab capacity and efficiency through its AI-driven analysis platform, EnsoSleep, which is already in use at over 500 sleep centers. Additionally, Inspire has provided seed funding to Ognomy, a platform that enhances access to sleep apnea care by facilitating remote diagnosis and treatment. These investments aim to bolster Inspire's digital health strategy, addressing the challenges faced by over 20 million Americans with obstructive sleep apnea.

Inspire Medical Systems, a leader in medical technology, announced that its management team will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 10:40 a.m. Pacific Time. The event will take place at the Encore Hotel in Las Vegas, Nevada and will feature a live webcast accessible through their website. Inspire specializes in innovative solutions for obstructive sleep apnea and offers the only FDA-approved neurostimulation therapy for this condition. A recorded version of the presentation will be available for two weeks post-event.

Inspire Medical Systems, Inc. (NYSE: INSP) will release its first-quarter 2022 financial results on May 3, after market close. Management will host a conference call at 5:00 p.m. ET to discuss these results and recent developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, showcasing its FDA-approved neurostimulation technology as a leading treatment option. For further details, visit Inspire's website.

Inspire Medical Systems reported a remarkable 70% revenue growth in Q4 2021, totaling $78.4 million, and a 102% increase for the full year 2021 at $233.4 million. The company activated 81 new U.S. implanting centers in Q4, exceeding guidance, and now operates a total of 684 centers. Inspire anticipates full-year 2022 revenue between $318 million and $326 million, projected growth of 36% to 40%. Despite challenges from the Omicron variant, Inspire's momentum and expanding market reach continue to drive its business forward.

Inspire Medical Systems (NYSE: INSP), a leader in medical technology for obstructive sleep apnea (OSA), will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on February 18, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast. Inspire's unique Inspire therapy is the only FDA-approved neurostimulation treatment for moderate to severe OSA, showcasing the company's commitment to innovative solutions. A replay of the presentation will be available for two weeks on Inspire's Investor website.

Inspire Medical Systems (NYSE: INSP) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, set for February 16, 2022. The management team will present at 11:20 a.m. Eastern Time, with a live webcast accessible for investors. The presentation will showcase Inspire's innovative solutions for patients with obstructive sleep apnea, including their FDA-approved neurostimulation technology, Inspire therapy. A replay will be available for two weeks on their investor website.

Inspire Medical Systems (NYSE: INSP) will announce its fourth quarter and 2021 annual financial results on February 8 after market close. A conference call will follow at 5:00 p.m. Eastern Time to discuss these results and recent developments. Inspire focuses on innovative solutions for patients with obstructive sleep apnea, offering the first FDA-approved neurostimulation therapy for moderate to severe cases. For more details, visit inspiresleep.com.

Inspire Medical Systems (NYSE: INSP) announced preliminary, unaudited revenue results for Q4 and full year 2021. Q4 revenue is expected to be between $78.0 million and $78.4 million, marking a 70% year-over-year increase. Full year revenue is projected at $233.0 million to $233.4 million, up 102% from 2020. The company activated 81 new U.S. centers in Q4, exceeding prior guidance. Inspire also received FDA approval for a Bluetooth-enabled remote control for its therapy system. Detailed financial results will be reported on February 8, 2022.